FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gernot Seipelt

Research Profile

Chemicals & Drugs

Disorders

Physiology

Haematopoiesis

Anatomy

Procedures

Antineoplastic Combined Chemotherapy Protocols

Activities & Behaviors

Drug Evaluation

Concepts & Ideas

Co-author Network

Publications

TOP 3
Salah-Eddin Al-Batran; Jörg Thomas Hartmann; R Hofheinz; N Homann; V Rethwisch; S Probst; Jan Stoehlmacher; M R Clemens; R Mahlberg; M Fritz; Gernot Seipelt; M Sievert; Claudia Pauligk; Akin Atmaca; Elke Jäger
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Salah-Eddin Al-Batran; Jörg Thomas Hartmann; Stephan Probst; Harald Schmalenberg; Stephan Hollerbach; Ralf Hofheinz; Volker Rethwisch; Gernot Seipelt; Nils Homann; Gerhard Wilhelm; Gunter Schuch; Jan Stoehlmacher; Hans Günter Derigs; Susanna Hegewisch-Becker; Johannes Grossmann; Claudia Pauligk; Akin Atmaca; Carsten Bokemeyer; Alexander Knuth; Elke Jäger
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Salah-Eddin Al-Batran; Akin Atmaca; Susanna Hegewisch-Becker; Dirk Jaeger; Sabine Hahnfeld; Mathias J Rummel; Gernot Seipelt; Andreas Rost; Jacqueline Orth; Alexander Knuth; Elke Jaeger
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gernot Seipelt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Salah-Eddin Al-Batran; Jörg Thomas Hartmann; R Hofheinz; N Homann; V Rethwisch; S Probst; Jan Stoehlmacher; M R Clemens; R Mahlberg; M Fritz; Gernot Seipelt; M Sievert; Claudia Pauligk; Akin Atmaca; Elke Jäger
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(11):1882-7.
2008: Salah-Eddin Al-Batran; Jörg Thomas Hartmann; Stephan Probst; Harald Schmalenberg; Stephan Hollerbach; Ralf Hofheinz; Volker Rethwisch; Gernot Seipelt; Nils Homann; Gerhard Wilhelm; Gunter Schuch; Jan Stoehlmacher; Hans Günter Derigs; Susanna Hegewisch-Becker; Johannes Grossmann; Claudia Pauligk; Akin Atmaca; Carsten Bokemeyer; Alexander Knuth; Elke Jäger
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1435-42.
2004: Salah-Eddin Al-Batran; Akin Atmaca; Susanna Hegewisch-Becker; Dirk Jaeger; Sabine Hahnfeld; Mathias J Rummel; Gernot Seipelt; Andreas Rost; Jacqueline Orth; Alexander Knuth; Elke Jaeger
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):658-63.
2002: Wolf-Karsten Hofmann; Gernot Seipelt; S Langenhan; Regina Reutzel; D Schott; O Schoeffski; Hans-Jochen Illiger; Frank Hartmann; Leopold Balleisen; Astrid Franke; Friedrich Fiedler; Christoph Huber; Herbert Rasche; Lothar Bergmann; Arnold Ganser; Christiane Pott; Rita Pasold; C Rudolph; Oliver G Ottmann; Nicola Gökbuget; Dieter Hoelzer
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Annals of hematology 2002;81(10):570-4.
2002: Eckhart Weidmann; Soo-Zin Kim; Andreas Rost; H Schuppert; Gernot Seipelt; Dieter Hoelzer; Paris S Mitrou
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1285-9.
2002: Steffen Koschmieder; Florian Fauth; Susanne Kriener; Dieter Hoelzer; Gernot Seipelt
Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
Leukemia & lymphoma 2002;43(3):645-7.
2002: Gernot Seipelt; Ulrich Germing; Steffen Koschmieder; Angelika Böhme; Carlo Aul; Dieter Hoelzer
Secondary acute myeloid leukaemia with monosomy 7 in identical adult twins.
British journal of haematology 2002;116(2):338-40.
2002: Kai Uwe Chow; Wolf Daniel Sommerlad; Simone Boehrer; Bernd Schneider; Gernot Seipelt; Mathias J Rummel; Dieter Hoelzer; Paris S Mitrou; Eckhart Weidmann
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Haematologica 2002;87(1):33-43.
2001: Steffen Koschmieder; Wolf-Karsten Hofmann; J Kunert; Sandra Wagner; K Ballas; Gernot Seipelt; Dieter Hoelzer; Oliver G Ottmann; Uwe Kalina
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS.
Leukemia 2001;15(6):942-9.
2001: Ulrich Mahlknecht; Eckhart Weidmann; Gernot Seipelt
The irreplaceable image: Black tea delays recovery from iron-deficiency anemia.
Haematologica 2001;86(5):559.
2001: Gernot Seipelt; Angelika Böhme; Steffen Koschmieder; Dieter Hoelzer
Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Annals of hematology 2001;80(3):170-3.
2001: Tilmann Heinrich Kirchner; Gernot Seipelt; T J Vogl
[Involvement of the facial skull in Erdheim-Chester disease].
Röntgenpraxis; Zeitschrift für radiologische Technik 2001;54(4):148-51.
2000: Wolf-Karsten Hofmann; Uwe Kalina; Steffen Koschmieder; Gernot Seipelt; Dieter Hoelzer; Oliver G Ottmann
Defective megakaryocytic development in myelodysplastic syndromes.
Leukemia & lymphoma 2000;38(1-2):13-9.
2000: Wolf-Karsten Hofmann; Gernot Seipelt; Oliver G Ottmann; Uwe Kalina; Steffen Koschmieder; J Brücher; N Frickhofen; M Klausmann; Paris S Mitrou; Dieter Hoelzer
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels.
Annals of hematology 2000;79(5):255-8.
2000: Gernot Seipelt; Oliver G Ottmann; Dieter Hoelzer
Cytokine therapy for myelodysplastic syndrome.
Current opinion in hematology 2000;7(3):156-60.
2000: Barbara Wassmann; Gernot Seipelt; F Länger; Mathias J Rummel; Angelika Böhme; Martin-Leo Hansmann; Dieter Hoelzer
[Pancytopenia, hepatosplenomegaly and fever in a 49-year old patient].
Der Internist 2000;41(3):304-8.
2000: Gernot Seipelt
Clinical use of hematopoietic growth factors.
Antibiotics and chemotherapy 2000;50():94-105.
2000: Arnold Ganser; G Heil; Gernot Seipelt; W Hofmann; JT Fischer; W Langer; W Brockhaus; K Kolbe; Thomas Ittel; N Brack; H G Fuhr; P Knuth; K Höffken; Lothar Bergmann; Dieter Hoelzer
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Annals of hematology 2000;79(1):30-5.
1999: Wolf-Karsten Hofmann; Uwe Kalina; Gernot Seipelt; K Hoffmann; Sandra Wagner; Dieter Hoelzer; Oliver G Ottmann
Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha.
European journal of haematology 1999;62(5):336-40.
1999: Wolf-Karsten Hofmann; Arnold Ganser; Gernot Seipelt; Oliver G Ottmann; C Zander; G Geissler; K Hoffmann; K Höffken; JT Fischer; G Isele; Dieter Hoelzer
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Annals of hematology 1999;78(3):125-30.
1999: Wolf-Karsten Hofmann; Uwe Kalina; Sandra Wagner; Gernot Seipelt; C Ries; Dieter Hoelzer; Oliver G Ottmann
Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes.
Experimental hematology 1999;27(3):395-400.
1998: Gernot Seipelt; Wolf-Karsten Hofmann; H Martin; Barbara Wassmann; A Boehme; Oliver G Ottmann; Dieter Hoelzer
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
Annals of hematology 1998;76(3-4):145-51.
1997: Oliver G Ottmann; Gernot Seipelt; Dieter Hoelzer
[Clinical administration of hematopoietic growth factors. When and where?].
Der Internist 1997;38(12):1160-7.
1996: Johannes Kirchner; Gernot Seipelt; Reinhard Heyd; Christoph F Dietrich; Volkmar Jacobi
[Disseminated pneumoperitoneum during the therapy of lymphoma with methotrexate and cytosine arabinoside].
Deutsche medizinische Wochenschrift (1946) 1996;121(42):1288-91.
1996: Arnold Ganser; A Maurer; C Contzen; Gernot Seipelt; Oliver G Ottmann; C Schadeck-Gressel; K Kolbe; R Haas; C Zander; R Reutzel; Dieter Hoelzer
Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
Annals of hematology 1996;72(4):237-44.
1995: Gernot Seipelt; Dieter Hoelzer
[Current aspects of therapy in chronic and acute leukemias].
Schweizerische medizinische Wochenschrift 1995;125(27-28):1354-63.
1995: Dieter Hoelzer; Gernot Seipelt
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia.
Current opinion in hematology 1995;2(3):196-203.
1995: A B Maurer; Arnold Ganser; Gernot Seipelt; Oliver G Ottmann; U Mentzel; G R Geissler; Dieter Hoelzer
Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors.
British journal of haematology 1995;89(3):449-56.
1995: Gerhard Heil; L Chadid; Dieter Hoelzer; Gernot Seipelt; Paris S Mitrou; C Huber; K Kolbe; Roland Mertelsmann; A Lindemann; J Frisch
GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).
Leukemia 1995;9(1):3-9.
1994: Gernot Seipelt; Arnold Ganser; H Duranceyk; A Maurer; Oliver G Ottmann; Dieter Hoelzer
Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.
Annals of hematology 1994;68(4):167-70.
1994: Arnold Ganser; Gernot Seipelt; W Verbeek; Oliver G Ottmann; A Maurer; K Kolbe; U Hess; S Elsner; R Reutzel; B Wörmann
Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
Leukemia 1994;8(3):369-75.
1993: A B Maurer; Arnold Ganser; R Buhl; Gernot Seipelt; Oliver G Ottmann; U Mentzel; RG Geissler; Dieter Hoelzer
Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
Leukemia 1993;7(11):1728-33.
1993: Gernot Seipelt; Arnold Ganser; H Duranceyk; A Maurer; Oliver G Ottmann; Dieter Hoelzer
Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3.
British journal of haematology 1993;84(4):749-51.
1993: Arnold Ganser; Oliver G Ottmann; Gernot Seipelt; A Lindemann; U Hess; G Geissler; A Maurer; J Frisch; G Schulz; Roland Mertelsmann
Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes.
Leukemia 1993;7(5):696-701.
1992: Arnold Ganser; A Lindemann; Oliver G Ottmann; Gernot Seipelt; U Hess; G Geissler; Lothar Kanz; J Frisch; G Schulz; F Herrmann
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study.
Blood 1992;79(10):2583-91.
1992: Arnold Ganser; Gernot Seipelt; Matthias Eder; G Geissler; Oliver G Ottmann; U Hess; Dieter Hoelzer
Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs.
Seminars in oncology 1992;19(2 Suppl 4):95-101.
1992: U Hess; Arnold Ganser; H G Schnürch; Gernot Seipelt; Oliver G Ottmann; S Falk; G Schulz; Dieter Hoelzer
Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).
British journal of haematology 1992;80(2):254-6.
1991: A Lindemann; Arnold Ganser; F Herrmann; J Frisch; Gernot Seipelt; G Schulz; Dieter Hoelzer; Roland Mertelsmann
Biologic effects of recombinant human interleukin-3 in vivo.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(12):2120-7.
1991: Arnold Ganser; Oliver G Ottmann; Gernot Seipelt; U Hess; G Geissler; Rolf Merget; S Falk; A Maurer; Matthias Eder; Dieter Hoelzer
Preclinical and clinical evaluation of interleukin 3.
Behring Institute Mitteilungen 1991;(90):50-61.
1991: Arnold Ganser; J W Janssen; Oliver G Ottmann; Gernot Seipelt; Matthias Eder; R Becher; A Lindermann; F Herrmann; G Schulz; Roland Mertelsmann
In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders.
Leukemia 1991;5(6):487-92.
1991: Dieter Hoelzer; Gernot Seipelt; Arnold Ganser
Interleukin 3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease.
Seminars in hematology 1991;28(2 Suppl 2):17-24.
1991: S Falk; Gernot Seipelt; Arnold Ganser; Oliver G Ottmann; Dieter Hoelzer; HJ Stutte; K Hübner
Bone marrow findings after treatment with recombinant human interleukin-3.
American journal of clinical pathology 1991;95(3):355-62.
1991: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; F Herrmann; Matthias Eder; J Frisch; G Schulz; Roland Mertelsmann; Dieter Hoelzer
Clinical effects of recombinant human interleukin-3.
American journal of clinical oncology 1991;14 Suppl 1():S51-63.
1991: Arnold Ganser; Gernot Seipelt; Dieter Hoelzer
The role of GM-CSF, G-CSF, interleukin-3, and erythropoietin in myelodysplastic syndromes.
American journal of clinical oncology 1991;14 Suppl 1():S34-9.
1991: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; Matthias Eder; F Herrmann; J Frisch; G Schulz; Roland Mertelsmann; Dieter Hoelzer
Recombinant human interleukin-3 in patients with hematopoietic failure.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1991;121():162-72.
1991: Gernot Seipelt; Arnold Ganser; Dieter Hoelzer
Hemopoietic growth factors in the treatment of acute leukemias and myelodysplastic syndromes.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1991;121():141-54.
1991: Arnold Ganser; Oliver G Ottmann; Gernot Seipelt; Matthias Eder; G Geissler; Rolf Merget; A Maurer; S Falk; A Lindemann; F Herrmann
Results of phase I/II trials with recombinant human interleukin-3.
Biotechnology therapeutics 1991;2(3-4):313-25.
1991: F Herrmann; Roland Mertelsmann; A Lindemann; Oliver G Ottmann; Gernot Seipelt; Wolfgang Oster; Dieter Hoelzer; Arnold Ganser
Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
Biotechnology therapeutics 1991;2(3-4):299-311.
1990: Oliver G Ottmann; Arnold Ganser; Gernot Seipelt; Matthias Eder; G Schulz; Dieter Hoelzer
Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo.
Blood 1990;76(8):1494-502.
1990: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; Matthias Eder; S Falk; F Herrmann; Joachim Peter Kaltwasser; P Meusers; M Klausmann
Effects of recombinant human interleukin-3 in aplastic anemia.
Blood 1990;76(7):1287-92.
1990: Arnold Ganser; A Lindemann; Gernot Seipelt; Oliver G Ottmann; F Herrmann; Matthias Eder; J Frisch; G Schulz; Roland Mertelsmann; Dieter Hoelzer
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure.
Blood 1990;76(4):666-76.
1990: Arnold Ganser; Gernot Seipelt; A Lindemann; Oliver G Ottmann; S Falk; Matthias Eder; F Herrmann; R Becher; K Höffken; T Büchner
Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.
Blood 1990;76(3):455-62.
1990: Gernot Seipelt; Oliver G Ottmann; Arnold Ganser; Matthias Eder; A Lindemann; S Falk; HJ Stutte; K Hübner; Roland Mertelsmann; Dieter Hoelzer
[In vitro and in vivo effects of recombinant human interleukin-3 on hematopoietic progenitor cells].
Verhandlungen der Deutschen Gesellschaft für Pathologie 1990;74():116-9.
1990: S Falk; Gernot Seipelt; Arnold Ganser; Dieter Hoelzer; HJ Stutte; K Hübner
[Effects on bone marrow during stimulation of hematopoietic stem cells with recombinant human interleukin-3].
Verhandlungen der Deutschen Gesellschaft für Pathologie 1990;74():111-5.
1990: Rolf Merget; A B Maurer; U Koch; Arnold Ganser; Oliver G Ottmann; Gerhard Schultze-Werninghaus; Gernot Seipelt; W Zachgo; Dieter Hoelzer; J Meier-Sydow
Histamine release from basophils after in vivo application of recombinant human interleukin-3 in man.
International archives of allergy and applied immunology 1990;92(4):366-74.
1989: S Falk; Gernot Seipelt; H Müller; HJ Stutte
Immunohistochemical assessment of splenic lymphocyte and macrophage subpopulations in patients with gastric cancer.
Cancer 1989;64(8):1646-51.